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ABSTRACT 
Tubedown (Tbdn) is a mammalian homologue of theN-terminal acetyl transferase 
subunit NA Tl of S. cerevisiae and copurifies with an acetyltransferase activity. Previous 
studies have demonstrated a suppression of Tbdn in the retinal blood vessels of patients 
with neovascular retinopathy including proliferative diabetic retinopathy (PDR) and 
retinopathy of prematurity (ROP). Moreover, conditional endothelial knockdown of Tbdn 
in the mouse blood vessel leads to retinal lesions similar to neovascular retinopathy, 
characterized by abnormal retinal vascular structures, an increase in numbers of retinal 
blood vessels, and thickening of the retinal tissues. These resu lts indicate that Tbdn is 
required for retinal homeostasis. Means to restore Tbdn expression and/or activity may be 
useful for treating neovascular retinopathy. Recent evidence from our lab suggests that 
Tbdn binds to the actin binding protein cortactin. Tbdn also has been shown to co-
localize with the actin cytoskeleton. The actin cytoskeleton is involved in regu lating cell 
permeability and tight junctions. A change in the permeability of endothelial cells has 
been shown to occur in neovascular PDR. In addition, tight junctions that are important 
for the blood-retinal barrier are also disrupted during the process of neovascularization. 
Therefore, this study investigated whether a decreased level of Tbdn increases the 
permeability of retinal endothelial cell layers. Our results indicate that knockdown of 
Tbdn expression in endothelial cells leads to a significant increase in cellular 
permeability measured by transit of FITC-albumin across a monolayer of retinal 
endothelial cells. Similarly, under in vivo conditions the extravasation of albumin was 
seen in retinal blood vessels of mice wherein Tbdn was conditionally knocked down in 
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the endothelium. Based on our findings we are proposing a model in which Tbdn act in 
concert with cortactin to regulate the permeability of FITC-albumin in the retinal 
endothelial cells via its conserved domains. Our results suggest that loss of Tbdn could 
have clinically relevant significance and Tbdn may be used as a future drug target. 
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CHAPTER! 
INTRODUCTION 
1.1 Retina and Neovascular pathology/diseases 
1.1.1 Anatomy of the retina 
The retina, being a highly differentiated organ, plays a major role in the visual 
system. It is located between the vitreous body (V) and the retinal pigmented epithelium 
(RPE) and is composed of seven layers; the nerve fiber layer (NFL), ganglion cell layer 
(GCL), inner plexiform layer (IPL), inner nuclear layer (JNL), outer plexiform layer 
(OPL), outer nuclear layer (ONL), and finally the outer segments of rods and cones (Fig. 
1-1 ). The retina is supplied by two major vascular structures; the choroidal circulation 
(CBV) and the retinal vasculature (RBV) (Fig.1-1 ) . The retina also contains a blood-
retinal barrier (BRB), which is similar to the blood-brain barrier (BBB) to maintain a 
neutral environment and to protect the neural retina from the circulating blood (Hosoya 
and Tomi, 2005). BRB can be further subdivided into two parts forming complex tight 
junctions of retinal capillary endothelial cells (forming inner BRB) and retinal pigment 
epithelial cells (forming outer BRB). BRB is responsible for regulating osmotic balance, 
ionic concentration and transport of nutrients, including sugars, lipids, and amino acids 
(Erickson, 2007). Similar to the BBB, the adjacent endothelial cells lining the BRB form 
a tight barrier junction to limit the permeability of fluids and solutes to the minimum 
(Harhaj and Antonetti, 2004). Breakdown of the BRB is seen in a number of diseases 
including retinal diseases with neovascularization (Harhaj and Antonetti, 2004; Erickson 
et al., 2007), which are usually associated with increased tissue permeability (Harhaj and 
Antonetti, 2004). Neovascularization involves angiogenesis or formation of new blood 
vessels from pre-existing vessels. This is a complex process that requires multiple steps. 
Briefly, during the initial phase of angiogenesis activated blood vessels are vasodilated 
with increased vascular permeability; surrounding matrix is then degraded leading to 
endothelial cell proliferation and subsequent migration (Erickson et al., 2007). 
CBV 
Sclera 
Bruch's 
RPE 
ONL 
INL 
GCL ----r-~--+ 
Choriocapillaries 
Photoreceptor layer 
(rods and cones) 
OPL 
IPL 
RBV 
NFL 
Figure 1-1. Structural features of the human eye. Hematoxylin and Eosin staining at 
400X showing different cell layers that comprise the retina (See text above for details). 
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1.1. 2 Ocular Neovascularization 
A number of ocular diseases share neovascularization as a common underlying 
pathology leading to vision loss. The most common among these are the proliferative 
diabetic retinopathy (PDR), age-related macular degeneration (AMD) and retinopathy of 
prematurity (ROP). Together these three diseases are the leading cause of blindness in 
North America (Bradley et al., 2007; Dorrell Metal., 2007) affecting people of all ages. 
PDR affects mostly adults of working age and is a complication resulting from diabetes 
mellitus. In the early and non-proliferative stage of the disease there is vasodilation, 
increased blood flow, tissue (macular) edema, and vascular permeability occurring 
(Gardner et al., 2002). However, as the disease progresses to a more advanced phase 
there is growth of new vessels which again have increased leakiness and leads to blurred 
vision and edema (Erickson et al. , 2007). In the final stages of the disease, detachment of 
the retina may occur causing severe sight-loss. In adults of >65years, AMD is the 
prevalent cause of blindness (Neely, 1998). AMD can occur in two forms: "wet" 
(neovascular) and "dry" (non-neovascular) AMD. In the case of the neovascular AMD 
abnormal choroidal blood vessels begin to grow under the centre of the retina or the 
macula, responsible for detailed central vision. Like in the PDR these newly formed 
vessels are fragile and leaky (more permeable) in nature. There is accumulation of fluid 
or edema in the macula causing damage to the macula and problems with vision follow. 
Approximately 85-90% of the patients who have AMD fall into the "dry" form category 
(American Macular Degeneration Foundation, http://www.macular.orgD. Dry AMD 
usually occurs before the development of wet AMD and it tends to progress more slowly 
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than the "wet" type. During the "dry" form of AMD, the retinal pigment epithelial cells 
(RPE) located in the macula breaks down due to the deposition of discrete regions of 
yellow pigmentation also known as drusen in the macula. This process causes thinning 
and drying of the macula, making it unable to function properly. Patients with this 
condition also have problems with their central vision, however this is not as severe as in 
the case of the "wet" AMD. Retinopathy of prematurity is a disease found in infants born 
prematurely. In humans, the development of retinal blood vessels takes place during the 
fourth month of pregnancy and reaches the retinal periphery just before birth (Chen and 
Smith, 2007). However, in premature babies retinal vasculature is poorly developed with 
a peripheral avascular region. As the infant matures, newly formed vessels grow into the 
avascular region of the retina. Over time, in severe and untreated cases, neovessels 
proliferate into the vitreous region leading to retinal detachment and blindness . There are 
many risk factors for developing ROP including, prematurity, hyperoxia, hypox ia, 
hypotension, acidosis, blood transfusions, sepsis, antioxidant deficiency, patent ductus, 
arteriosus and apnea (Chawla et al. , 2008). 
1.1. 3 Molecular basis of neovascular retinopathy 
The exact cause of neovascular retinopathies remains to be explored. There are 
however speculations that genetic factors may be involved for the onset of ROP; since 
skin pigmentation plays an important role in the development of ROP with Caucasian 
infants more likely to develop the disease compared to African American infants, as well 
twins that have a higher concordance rate for acquiring the disease (Good and Gendron , 
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2007). Similarly, there is a growing amount of evidence linking genetic variants to the 
development of AMD (Swaroop et al., 2007) and polymorphisms of the human vascular 
endothelial growth factor (VEGF) gene have been shown to increase the development of 
PDR in diabetic patients (Szaflik et al., 2007). In particular, in the case of AMD there is 
strong evidence associating complement factor H (CFH) and locus LOC387715/ HTRA 1 
to the disease risk of AMD (Swaroop et al., 2007; Scholl, 2007). CFH is an important 
protein for regulating the complement system and is involved in the immune-
inflammatory processes. This is consistent with the fact that AMD is characterized by 
choroidal neovascularization which occurs due to a chronic inflammatory response within 
the Bruch membrane (inner most layer of the choroid) and the choroid layer, the vascular 
layer found between the sclera and the retina (Montezuma et al. , 2007). 
Currently, some of the key proteins that are thought to contribute to retinal 
pathogenesis include vascular endothelial growth factor (VEGF), erythropoietin, insulin-
like growth factor- I (IGF-1 ), hepatocyte growth factor (HGF), angiopoietin, platelet-
derived growth factor (PDGF) (Kvanta, 2006) and fibroblast growth factor (FGF) (Neely, 
1998). VEGF in particularly is a potent inducer of permeability and has been found to be 
a key contributor of angiogenesis (Bhisitkul, 2006; Andreoli and Miller, 2007; Erickson 
et al. , 2007, Shukla et al. 2007). It is part of a family of proteins that consists of VEGF-A, 
VEGF-B, VEGF-C, VEGF-D, and PIGF and act through the tyrosine kinase receptors 
VEGFR-1 , VEGFR-2, and VEGFR-3 (Andreoli and Miller, 2007). It is the proper 
balance of the pro- and anti-angiogenic regulators, which is crucial for maintaining 
homeostasis of the blood vessels. Since, angiogenesis occurs in multiple steps involving a 
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wide range of factors and pathways, it will be ineffective to target just one regulator 
affecting this process. Plus, current treatments are only focusing on growth factors 
mentioned above and fail to take into account other important homeostatic regulators, 
which may be implicated in these diseases. In order to develop treatment that will be 
useful against the nature and complexity of the neovascularization, it is not only 
necessary but also essential to find other targets, which will have a more global effect on 
the disease state. One such homeostatic protein has been isolated in our lab and is named 
Tubedown (Tbdn). 
1.1. 4 Currently available treatments for retinal diseases 
The need for better treatment for neovascular retinopathies is crucial since current 
therapeutic strategies targeting these diseases are either limited or non-existent. Laser 
photocoagulation therapy uses a thermal (heat) laser to destroy the newly formed vessels 
caused by AMD. This form of therapy is only partially effective against reducing 
blindness and may actually damage the retina since laser has to reach the blood vessels 
that are embedded underneath the retina. Patients often develop complications associated 
with the treatment and poor visual acuity remains (Chen and Smith, 2007). Photodynamic 
therapy was developed to prevent the damages resulting from the laser photocoagulation 
therapy . However, this procedure requires multiple treatments administered every 3 
months (Bradley et al. 2007) and hence can be considered a nuisance for patients and 
their family. Even with treatments vision improvements rarely occur (Bradley et al. 
2007). There is currently no cure for PDR and ROP. 
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Anti-vascular endothelial growth factor (Anti-VEGF) therapy is an attractive and 
emerging therapy for neovascular ocular diseases. However, due to the limited number 
of trials with the anti-VEGF therapy the long-term benefits and safety of this type of 
therapy remain to be assessed. To date only Macugen (Pegaptanib sodium injection) and 
Lucentis (Ranibizumab injection) are the only two Foods and Drug Administration 
(FDA) approved drugs available for the treatment of AMD (Andreoli and Miller, 2007). 
Ranibizumab is a 48-kDa recombinant, humanized monoclonal anti-VEGF binding 
fragment (Kaiser et al ; 2007). It binds to and inhibits the biologic activity of all isoforms 
of human VEGF-A by inhibiting the interaction between VEGF-A and its receptors, 
which is responsible for processes such as endothelial cell proliferation, migration, and 
survival of cell receptors (Kourlas and Abrams, 2007). A few large, randomized trials 
have shown the efficacy and safety of the Ranibizumab for clinical use in AMD (Ia Cour, 
2007; Kourlas and Abrams 2007). Another drug named Avastin (Bevacizumab) was 
approved by FDA in 2004 for the treatment of colorectal cancer (Hussain, 2007). 
Bevacizumab is a full-length , humanized monoclonal antibody, which is also 
directed against all the biologically active isoforms of VEGF-A . The clinical results for 
AMD with Bevacizumab are similar to the ones with Ranibizumab (Packer and Jampol, 
2008). Majority of the published reports regarding Bevacizumab are however, 
uncontrolled, non-randomized or small case reports (Nagpal, 2007; Packer and Jampol , 
2008). Due to this lack of large randomized trials, Bevacizumab has not been approved 
by the FDA for intraocular use (Andreoli and Miller, 2007). On the other hand, it is 
widely used as an off-label drug for various ophthalmic diseases which is the main factor 
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for its cost being very low compared to other FDA approved drugs for eye diseases 
(Nagpal, 2007). The off-label status of Bevacizumab is responsible for the continuous 
controversy and ethical dilemma regarding the application of this drug for intraocular 
use. 
Moreover, predicted statistics on the development of ocular diseases with 
neovascularization is staggering. For instance, it is estimated that by 2025 the incidence 
of diabetes worldwide will be in - 334 million people and 30.3 million people in the 
United States of which 25% will display PDR and hence will require effective treatment 
(Bradley et al. 2007). However, effective and successful development of pharmacological 
treatments will require a better knowledge of the molecular mechanism or factors 
responsible for causing ocular neovascularization. We investigate here the role of such an 
important factor known as Tubedown, in order to gain a better understanding of retinal 
diseases with neovascularization. 
1.2 Tubed own 
1.2.1 What is Tubedown? 
Tubedown (Tbdn), also referred to as mNatl , NATH and Nargl is a 100-kDa novel 
acetyltransferase protein originally identified from an embryonic endothelial cell line 
(IEM) (Gendron et al., 2000). It displays homology to Nat I of yeastS. cerevisae, which 
forms a complex with the acetyltransferase Ard I to form the essential subunit of the yeast 
N-terminal acetyltransferase NatA (Park and Szostak, 1992; Gendron et al. , 2000). In the 
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mammalian system, Tbdn shows a great extent of homology to mNat2 (70% identity) and 
Ard 1 has been reported to show 81% identity with Ard2 (Sugiura et al. , 2003 ; Arnesen et 
al. , 2006). In yeast, NatA likely mediates co-translational acetylation of nascent 
polypeptides at specific residues in the second position of the N-terminus upon cleavage 
of the initial methionine by methionine aminopeptidases (Gautschi et al. 2003 ; Polevoda 
et al., 2003). Acetylation of lysine residues has also been suggested as a function of Ard 1 
and a wide variety of potential substrates for NatA have been reported (Polevoda et al. , 
2003 ; Kimura et al. , 2003 ; Wang et al. , 2004; Geissenhoner et al. , 2004; Lim et al. , 
2006). Recently, another protein found in association with the NatA complex is the 
putative acetyltransferase Nat5 (also called San in D. melanogaster) which interacts with 
Natl in the yeast ribosome (Gautschi et al. 2003; Williams et al., 2003 ; Arnesen et al. , 
2005; Arnesen et al. , 2006c; Hou et al, 2007). Both in the yeast and in mammalian cell 
lines, Tbdn acts in a complex with the acetyltransferase Ard I and is involved in the 
regulation of a wide range of cellular processes including cell growth and differentiation 
(Park and Szostak, 1992; Paradis et al. , 2002; Willis et al. , 2002; Sugiura et al. , 2003 ; 
Gautschi et al. , 2003; Kimura et al. , 2003 ; Wang et al. , 2004; Asaumi et al. , 2005 ; 
Arnesen et al. , 2005; Arnesen et al., 2006b). In 2000, Gendron et al. tested the acetylation 
activity of Tbdn in an embryonic endothelial cell line and found that immunoprecipitates 
prepared with anti-Tbdn antibody display an acetyl transferase activity, confirming the 
presence of acetylation activity in the mammalian cell line. Acetylation of transcription 
factors is in turn one of the most significant processes regulating gene expression 
(Gregory et al. , 2001). Acetylation has been shown to play a wide variety of role in 
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nuclear import, protein-protein interaction and protein stability (Gregory et al., 200 I). 
Further, lack of acetyl transferase due to a defect in either the nat I or ard I gene leads to 
similar phenotypes resulting in abnormal cell cycle control and lack in sporulation 
(Whiteway and Szostak, 1985; Whiteway et al. , 1987; Mullen et al., 1989) indicating that 
both gene products perform a common function in yeast (Mullen et al., 1989) and in the 
mammalian system (Asaumi et al., 2005; Arnesen et al., 2005). 
1.2.2 Tubedown expression 
The expression of Tbdn has been studied in a number of embryonic and adult 
tissues (Gendron et al., 2000; Gendron et al., 2001; Paradis et al., 2002) at both RNA and 
protein level. The results indicate that the expression of Tbdn is developmentally 
regulated during embryogenesis while during adulthood high levels appear to be limited 
to only few tissues including the ocular endothelium, blood vessels of regressing ovarian 
follicles and the choroid plexus endothelium (Gendron et al., 2000; Gendron et al., 200 I ; 
Paradis et al., 2002; H. Paradis, personnel communication). Tbdn is also transiently 
expressed during embryogenesis in the developing vasculature and neuronal tissues 
where its regulation is associated with differentiation (Gendron et al, 2000; Sugiura et al., 
2003; Arnesen et al., 2006; Martin et al, 2007). The high level of Tbdn expression in 
these tissues may suggest a unique role for Tbdn in these particular areas and more 
importantly in the retinal blood vessels. 
10 
1.2.3 Function ofTubedown 
The functional role of Tbdn is still being investigated. Although some information 
now exists on its role in growth and differentiation as well as its importance in 
maintaining the ocular homeostasis, the full mechanistic pathways to explain these 
processes still remain to be explored. Earlier studies looking at the expression level of 
Tbdn in healthy and diseased retinal blood vessels may help shed some light on its role in 
vascular remodeling and angiogenesis (Fiuge et al., 2002; Paradis et al., 2002; Wall et al., 
2004; Gendron et al., 2006). In one study, in vitro capillary formation in embryonic 
endothelial cells as well as in retinal endothelial cells was investigated where Tbdn 
showed significant downregulation during capillary growth suggesting it may play a role 
in vascular remodeling (Gendron et al. , 2000). In addition, clones of the RF/6A fetal 
choroid-retina endothelial cell line showing suppression of Tbdn levels after 
overexpression of an antisense TBDN eDNA display a significant increase in the 
formation of capillary-like structures in vitro compared with controls (Paradis et al. , 
2002). Further, Wall et al. (2004) generated a bitransgenic mouse model that enables 
conditional knockdown of Tbdn specifically in endothelial cells. Their results indicated 
that mice with suppression of Tbdn displayed retinal and choroidal neovascularization 
with intra- and preretinal fibrovascular lesions similar to human proliferative 
retinopathies. Retinal lesions observed in Tbdn suppressed mice increased in severity 
with prolonged suppression of Tbdn. In comparison to normal retina, the retinal lesions 
displayed alterations in the basement membrane of blood vessels and in the distribution 
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of glial and myofibroblastic cells. When Tbdn expression was studied in diabetic adult 
human eye specimens in parallel with the normal samples, it was found that there is a 
significant suppression of Tbdn in retinal blood vessels of human specimens of 
neovascularization PDR (Gendron et al. , 200 I) . Likewise, the expression of Tbdn was 
characterized in neonatal retinal neovascularization using a hyperoxia-induced 
retinopathy mouse model and human specimen of stage 3 ROP (Gendron et al. , 2006). 
Again, the authors observed downregulation of Tbdn expression in the mouse model , 
which was accompanied by increased neovascularization and retinal thickness. The 
human sample also showed a lower level of Tbdn staining compared to the age-matched 
control. Loss of Tbdn expression is again seen in human specimens of AMD compared to 
age-matched controls (H. Paradis, personnel communication). Taken together, these 
studies clearly indicate that suppressed levels of Tbdn is associated with angiogenesis and 
pathological neovascular retinopathies (Gendron et al., 2001; Paradis et al. , 2002; Wall et 
al. , 2004; Gendron et al. , 2006) as well , highlights the importance of Tbdn in maintaining 
the homeostasis of the retinal blood vessels. 
Recently, Asaumi et al. (2005) investigated the role of ARD 1 and Tbdn in the 
endocytosis of beta-amyloid precursor protein and its effect on amyloid beta protein 
secretion. They reported that coexpression of the human homologues of the yeast Ard 1 
and Tbdn in cells suppressed amyloid beta secretion and inhibition of endocytosis of cell-
surface amyloid precursor protein was also seen. This suppression correlated with the 
enzyme activity of Tbdn and Ard I . This is a significant piece of evidence indicating a 
possible functional role for Tbdn in membrane trafficking. Moreover, Paradis et al. 
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(2008) showed that Tbdn forms a complex with the actin binding protein cortactin. 
Cortactin is known to be important for regulating the actin cytoskeleton dynamics (Weed 
and Parsons, 200 I; Daly 2004) and by doing so it is involved in processes requiring 
plasma membrane remodeling such as cell migration, endocytosis and in intracellular 
movement of vesicles (Weed and Parsons, 2001; Daly, 2004; Kessels and Qualmann, 
2005 ; Kowalski et al. , 2005; Mehta and Malik, 2006). Since, cortactin is also implicated 
in endothelial permeability and migration (Daly, 2004; Kowalski et al. , 2005 ; Mehta and 
Malik, 2006), it is tempting to ask the question "whether there is a possible role for Tbdn 
in the vesicle transport mechanism including endothelial permeability?" To be able to 
answer this question it is necessary to closely look at the current transport mechanisms. 
1.3 Vascular Permeability/ Rationale for current study 
The vascular system of our body originates from and is largely mediated by the 
endothelial cells, which plays a major role in regulating various homeostatic functions 
including the control of vasomotor tone, the trafficking of cells and nutrients, the 
maintenance of blood fluidity, the growth of new blood vessels (Cines et al. , 1998) as 
well as transport of plasma molecules, employ bidirectional receptor-mediated and 
receptor-independent transcytosis and endocytosis (Simionescu and Antohe, 2006). When 
endothelial cells fail to maintain the homeostasis, it leads to a number of patho-
physiological conditions such as inflammation, cardiovascular diseases (Esper et al. , 
2006 and Trepels et al. , 2006) and angiogenesis (Polverini , 1995; Lee et al. , 1998; 
Lamalice et al. , 2007). As mentioned above, ocular diseases such as ROP, PDR, and 
13 
AMD are responsible for majority of the vision loss in the general population (Erickson 
et al., 2007). The blood-retinal barrier is greatly compromised in these diseases as an 
imbalance in nutrients and oxygen demand/supply occur which leads to angiogenesis 
(Erickson et al., 2007). In order to understand the molecular events leading to 
angiogenesis and increased vascular permeability, it is important to understand 
permeability pathways. 
Permeability is defined as the transport of solutes and water across endothelial 
and epithelial layers and arranged via 2 distinct pathways (Fig. 1-2). The paracellular 
pathway is mediated by tight junctions and here solutes pass through the lateral spaces 
between the contacting cells. On the other hand, via the transcellular route molecules pass 
from apical to basal cell membranes and are mostly regulated by channels, carriers, 
pumps and vesicles. Simionescu (1979) originally coined the term transcytosis, which 
involves the transport of large molecules by membrane-bound vesicles and require both 
endocytosis and exocytosis (Predescu et al., 2007). More specifically transcellular 
mechanism consists of the following steps; invagination of the plasma membrane, 
formation of a sealed vesicle by membrane fission, intracellular movement of the vesicle 
across the cell, followed by fusion of vesicle membrane with the plasmalemma on the 
opposite front of the EC, and discharge of vesicular content into the extracellular space 
(Predescu et al., 2007) (Fig. 1-2). Transcytosis is not limited to one particular cell type as 
previous reports show this process to occur in epithelial cells, osteoclasts, neurons 
(Predescu et al., 2007) and endothelial cells (Mehta and Malik, 2006). 
Transcytosis of albumin is a well-documented system and is of particu lar interest 
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to us because transcytosis of albumin has been shown to occur in the eye (Vinores et al. 
1998). Albumin is the most abundant protein in human plasma making up for 60% of the 
total protein content (Mehta and Malik, 2006). Plasma albumin acts as a carrier protein 
for a variety of hydrophobic molecules, enzymes and hormones across the endothelium 
(Mehta and Malik, 2006). Further evidences on the function of albumin indicate that it is 
implicated in controlling the endothelial barrier stability as well as plays an important 
role in maintaining the oncotic pressure across the capillaries (Mehta and Malik, 2006). 
Legend: 
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Figure 1-2. Permeability Pathways. Illustration shows transcytosis of albumin where, 
transcellular permeability is regulated by specific receptors found on the cell-surface. 
After ligand (albumin) binds to receptor (gp60), it is internalized (vesicle), shuttled across 
the cell and released on the other side of the cell membrane. In the paracelluJar 
permeability passive movement of molecules occur through the junctions (mediated by 
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Z0-1 and Occ1udin) found between adjacent cells. 
In contrast, tight junctions also known as Zonula Occludens found on most apical 
component of intercellular junctional complex are associated with paracellular 
permeability. They play a pivotal role in membrane compartmentalization and serve as 
barriers in epithelial and endothel ial cells. For instances, the blood- brain barrier (BBB) 
and the blood- retinal barrier (BRB) are mainly composed of tight junction structures 
(Harhaj and Antonetti , 2004). Both of these barriers are strictly regulated and allow 
minimal vesicular transport, characterized by transcellular flux across the retinal barrier, 
to occur (Ishibashi et al., 1980). Tight junctions consist of proteins such as Z0-1, 
occludin, claudins, JAM-I and others. These and other proteins associated with tight 
junctions are connected to components of the cytoskeleton and hence serve as essential 
link to other cell-cell and cell-substratum adhesion sites (Schneeberger and Lynch, 2004). 
Moreover, a wide range of cytoplasmic molecules which are a part of these junctions 
modulate a variety of cellular processes such as transcription, cell proliferation, cell 
polarity and the formations of a regulated diffusion barrier (Schneeberger and Lynch, 
2004). The paracellular pathway may be regulated directly through modification of tight 
junction proteins, or indirectly through effects on the cytoskeleton (Harhaj and Antonetti , 
2004). In 2005, Yu et al. investigated the role of the cytoskeleton on the pathogenesis of 
diabetic retinopathy using the streptozotocin-induced rat model. The authors observed 
changes in the F-actin cytoskeleton, which are filamentous polymers and are essential 
part of the actin cytoskeleton component to occur early in rats with diabetic retinopathy 
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and this alteration has been associated with microvascular leakage m the retinal 
capillaries. 
The present study, looking at the role of Tbdn in the permeability of endothelial 
cells was carried out with the hope to further understand and characterize the function 
and the mechanism of action of our protein of interest in health and disease. The cellular 
expression of Tbdn, at the leading edge of cell membranes and also in the perinuclear 
regions indicate its interaction with proteins involved in regulating the actin cytoskeleton. 
Recent data from our lab also show Tbdn acting in complex with cortactin, an actin 
binding protein (Paradis et al., 2008). Since originally being described as a filamentous 
actin binding protein and substrate of the tyrosine kinase pp60src in primary embryo 
fibroblasts, smooth muscle cells and endothelial cells (Wu and Parsons, 1993), the 
functional role of cortactin in regulating the dynamics of the actin cytoskeleton assembly 
has become well established (Weed and Parsons, 200 I ; Daly 2004). By regulating the 
actin cytoskeleton, cortactin is involved in processes requiring plasma membrane 
remodeling such as cell migration and endocytosis and in intracellular movement of 
vesicles (Weed and Parsons, 200 I; Daly, 2004; Kessels and Qual mann, 2005 ; Kowalski 
et at. , 2005; Mehta and Malik, 2006). Cortactin function is mediated through its 
interaction with Arp2/3 complex, N-WASP and diverse proteins associating with its SH3 
domain such as dynamin (Weed and Parsons, 2001 ; Daly, 2004; Kessels and Qualmann, 
2005, Mehta and Malik, 2006). The immunofluorescence staining analyses revealed that 
Tbdn co-localizes with cortactin in the cytoplasm and that the co-localization is most 
intense at the cortex and in perinuclear regions of cultured retinal endothelial cells 
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(Paradis et al. 2008). The co-localization of Tbdn and cortactin at perinuclear regions 
indicates that the complex might play a role in organelles surrounding the nucleus such as 
the endoplasmic reticulum and Golgi apparatus. In agreement with this hypothesis, the 
yeast NatA complex has been shown to be involved in ribosome biogenesis (Gautschi et 
al. , 2003; Polevoda et al, 2007). In addition, Tbdn co-localizes with the F-actin 
cytoskeleton in the cytoplasm. The actin cytoskeleton is in turn involved in regulating 
cell permeability and tight junctions (Clements et al., 2005; Yu et al., 2005; Clark et al., 
2007; Tyagi et al., 2008, Madara et al. , 1986). Since cortactin is also known to regulate 
cellular permeability through its interaction with the actin cytoskeleton, which is critical 
for endothelial cell homeostasis, the role of Tubedown on endothelial cell permeability 
was examined. In addition, since previous studies have shown Tbdn suppression leading 
to many ocular diseases (Wall et al. , 2004; Gendron eta/. , 200 I ; Gendron et al. , 2006), 
we hypothesize that the expression level of Tbdn is an important factor regulating 
permeability either through the paracellular pathway or the transcellular pathway and 
hence is a required component for maintaining ocular homeostasis. Studying Tbdn and its 
role on the permeability of the endothe lial cells may help us to better understand 
pathologies of the ocular diseases and subsequently will allow development of new 
pharmacological strategies to treat ocular retinopathies. 
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CHAPTER2 
MATERIALS AND METHODS 
2.1 Cell culture 
RF/6A rhesus macaque choroid-retina endothelial cells, an immortalized cell line 
were obtained from American Type Culture Collection (Massas, VA). Cells were grown in 
Dulbecco's Modified Eagle Media (DMEM) (Invitrogen) supplemented with 4 mM 
glutamine plus I 0% fetal bovine serum (FBS) and 50 f.!M of nonessential amino acids. 
Cells were maintained at 37°C in 10% C02 atmosphere. The antisense clones with 
suppressed level of Tbdn were derived in our Jab by stably transfecting RF/6A cells with 
a vector harboring a TBDN eDNA fragment in an antisense fashion (ASTBDN) (Parad is et 
al. , 2002). 
2.2 Permeability Assay 
To determine the effect of the antisense TBDN construct knockdown for Tbdn on 
RF/6A permeability, an in vitro permeability assay using FITC-labeled albumin was 
performed. RF/6A cells (parental cells, stable ASTBDN clones and control clones) were 
seeded onto 1 %-gelatin-coated polystyrene filter inserts (Costar Transwell, no. 34 70, 6.5 
mm diameter, 0.4 Jlm pore size, Sigma, St. Louis, MO) at a density of 30,000 cells/ insert 
(0.3 x 106 cells/ml) (Fig. 2-1 ). The cells were grown to confluence on the Transwell 
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inserts over 24 hours. The integrity of the cellular monolayer was evaluated for 
confluence by phase contrast light microscopy and photographed. Cells were then washed 
3 times in serum-free DMEM and the inserts were transferred into new 24-well plates 
containing serum-free DMEM and incubated for 2 hours. FITC-labeled albumin (Sigma 
A9771 , Sigma, St. Louis, MO) suspended in serum-free DMEM was added to the 
endothelial cell mono layers to achieve a final FITC-albumin concentration of 100 J.!M 
(Irwin et al., 2005). Transit rate of FITC-albumin across the monolayer was assessed by 
measuring the increase in FITC-albumin in the lower well at different time points from 0 
to 60 min (Irwin et al., 2005). FITC-albumin was quantified against a standard curve of 
FITC-albumin using a FLUOstar Optima spectrofluorometer (BMG Labtechnologies) at 
an excitation wavelength of 485 run and an emission wavelength of 520 run . 
• 
• 
.._ _ _. ______ Transwell insert 
Upper chamber 
E::;;;s;;~~~-,r-----Cell monolayer 
Lower chamber 
FTTC-Aihurnin • 
• • 
• • 
• • 
Figure 2-1. Transwell system used for permeability assay. RF/6A cells (parental cells, 
stable ASTBDN clones and control clones) were plated in the top chamber overnight. 
FITC-albumin at a final concentration of 100 J.!M was added the next day and the 
intensity of the tracer was measured by spectrofluorometer. 
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2.3 Immunofluorescence Staining 
To follow FITC- albumin distribution intracellularly, RF/6A cells were cultured 
overnight at 0.3 x 106 cells/ml on 18 mm coverslips. Next day cell layers were washed 
three times with serum-free DMEM and incubated 2 hrs at 37°C. I 00 11M FITC-albumin 
(Sigma) was added to the cell layer. Cells were incubated for T= 60 min then washed 3 
times with PBS. Cells were then fixed with 4% paraformaldehyde for 15 min after which 
they were incubated with PBS containing 0.1 % TritonX-1 00 for 15 min and stained with 
2.5 11M Phalloidin-TRJTC (Sigma). After 40 min of incubation, cells were washed again 
3 times with PBS and mounted in Vectashield (Vector laboratories, CA) and sealed with 
nail polish. All steps were performed at room temperature unless otherwise indicated. For 
double-labeling experiments, RF/6A parental cells were plated at 0.75 x 106 cells/mi. 
Coverslips were incubated overnight with either a mouse monoclonal OE5 antibody 
(Martin et al. 2007) against Tbdn at 15 jlg/ml or a negative control isotype-matched 
IgG2a antibody at 15 jlg/ml (DAKO, Mississauga Ontario, Canada). Fluorescence was 
visualized with a Leica DMIRE2 microscope (Germany) connected to a Qimaging 
RETIGA Exi camera. Images were viewed with a 40X objective and image data 
processed with the Openlab software (Version 3.1.3, Improvision; Lexington, MA, USA). 
2.4 Western blot Analysis 
Protein extraction was performed as described previously (Gendron et al., 2000). 
Cell extracts were prepared using TNB 0.5% lysis buffer (50 mM Tris [pH 7.6], 150 mM 
NaCl, 0.5% Brij 96) supplemented with protease inhibitors (lmM phenylmethylsulfonyl 
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fluoride [PMSF], I 0 flg/ml aprotinin and I 0 Jlglml leupeptin) and phosphatase inhibitors 
(2 mM sodium orthovanadate, 50 mM sodium fluoride, and 25 mM B-glycerophosphate). 
Lysates were clarified by centrifugation, protein concentration of supernatant was 
quantified and samples separated by SDS-PAGE. Western blot analysis was performed 
by standard procedures using chemiluminescence detection (ECL Plus reagent; 
Amersham Pharmacia Biotech, Piscataway, NJ). To ensure loading equivalency, Western 
blots were stripped and reprobed with ERK-1 rabbit polyclonal antibody (Santa Cruz 
Biotech, CA) and a-tubulin mouse monoclonal antibody (Sigma, St. Louis, MO). Z0-1 
antibody was used at 1:500 (Santa Cruz Biotech, CA, Cat.# Sc-33725). For detection of 
Tbdn an affinity-purified rabbit anti-Tbdn C I 0-20 antibody (Gendron et al. 2000, Paradis 
H. et al. 2008) was used and for detecting ARD 1 band affinity-purified goat anti-Ard 1 
antibody (Santa Cruz Biotechnology, Santa Cruz, CA). Densitometry analyses were done 
using the Kodak Gel Logic 200 Imaging System (Eastman Kodak Company, Rochester, 
NY) and intensities of the expressed bands were analyzed using Kodak Molecular 
Imaging Software (Version 4.0, Eastman Kodak Company, Rochester, NY). 
2.5 Immunostaining of eye sections with anti-albumin antibody 
Paraffin sections of eyes from doxycycline-fed endothelial-specific Tbdn 
knockdown mice and control mice sacrificed at 1 0 months were processed for 
immunostaining as described previously (Wall et al. , 2004) and analyzed by albumin 
immunohistochemistry to assess retinal albumin expression/localization. Mouse tissues 
were fixed in 4% paraformaldehyde, embedded in paraffin and processed for 
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immunohistochemistry, as previously described (Paradis et al., 2002). Briefly, sections 
were dewaxed in xylene and rehydrated in graded alcohols. Endogenous peroxidases 
were blocked in 0.3% H20 2 for I 0 min followed by post-fixation with 4% 
paraformaldehyde for I 0 min. Sections were incubated for I hour with 6% fat-free skim 
powdered milk in I 0 mM Tris HCI pH 7.6, 150 mM NaCI, 0.05% Tween 20 (TBST) for 
blocking nonspecific binding sites followed by incubation with goat anti-albumin 
horseradish peroxidase-conjugated antibody (GeneTex Inc. , San Antonio, TX) in 3% 
powdered milk/TBST overnight at room temperature. The peroxidase activity was 
detected using NovaRed substrate kit (Vector Laboratories, Burlingame, CA) according 
to the manufacturer's instructions. Negative control for the albumin staining was goat-
anti-rabbit horseradish peroxidase-conjugated antibody (Promega). Sections were then 
air-dried and mounted in Permount (Fisher Scientific, Pittsburg, PA). Adjacent sections 
were stained with hematoxylin and eosin to assess tissue integrity and pathology. The 
care and use of animals in this study followed the guidelines set by the Canadian Council 
on Animal Care and were approved by the Institutional Animal Care Committee of 
Memorial University of Newfoundland. 
2.6 FITC-Aibumin uptake experiment 
Intracellular FITC-albumin content was measured using a procedure adapted from 
Takano et al., 2002. RF/6A cells were plated at 0.75 x I 06 cells/ml on 35 mm culture 
dishes. The cells were grown to confluence over 24 hrs. Cells were then washed three 
times in DMEM and incubated for 2 hours. I 0 J.!M FITC-albumin was added to the plates 
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and cells were incubated for 0 to 120 min at 37°C. After each incubation period, the 
dishes were rinsed rapidly three times with 1 mL of ice-cold PBS. The cells were then 
scraped in ice-cold PBS and centrifuged at 4°C for 5min. Cells were lysed with PBS 
containing 0.1% Triton X-1 00 and the fluorescence of the homogenates was measured as 
described above. Protein quantitation was done by using the Bio-Rad protein assay kit 
(Bio-Rad Laboratories, Hercules, CA). 
2. 7 Statistical Analysis 
Differences between experimental groups were analyzed for statistical 
significance using the two-tailed Student's t test by the Microsoft Excel program. Values 
were expressed as the mean percentage of the control ± standard error of the mean 
(s.e.m.) except for the FITC-albumin uptake experiments where values are expressed as 
mean of pmol / flg of protein ± s.e.m. Differences were considered significant at P<0.05 . 
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CHAPTER3 
RESULTS 
3.1 Transcellular permeability of RF/6A endothelial cells. The role of 
Tubedown on the permeability of endothelial cells is unknown. However, a recent study 
by Asuami et al., suggested Tbdn being involved in the regulation of the endocytosis of 
beta-amyloid precursor transmembrane protein (Asaumi et al. , 2005). Since transcellular 
permeability requires endocytosis, these findings prompted us to study the ro le of Tbdn 
expression on the permeability of endothelial cells in vitro and in vivo. As a first step, an 
in vitro permeability assay was used to measure the transit of FITC-albumin across 
mono layers of RF/6A endothelial cell clones in which Tbdn expression had been knocked 
down by stable expression of an antisense TBDN eDNA construct ASTBDN (Parad is et 
al., 2002; Wall et al. , 2004). As shown in other cellular systems (Arnesen et a l., 2006c; 
Hou et al., 2007; Polevoda et al., 2007), the knockdown of Tbdn protein expression in 
RF/6A cells is associated with the suppression of Ard I protein expression (Fig.3- 1 A, B). 
The knockdown of Tbdn in RF/6A endothelial cells resulted in a significant increase in 
the percentage of FITC-albumin transit across the cellular monolayers compared to the 
RF/6A parental cell line and negative control RF/6A clones in which Tbdn expression 
was not suppressed (Fig. 3-2 and 3-3). Differences were considered significant at P<0.05. 
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3.2 Immunofluorescence localization of FITC-albumin in RF/6A cells. As 
previously reported for endothelial cells (Mehta and Malik, 2006), both fluorescence 
microscopy of RF/6A cells incubated with FITC-albumin and measurement of 
intracellular uptake of FITC-albumin by RF/6A cells indicated that the permeability of 
endothelial cells to FITC-albumin was mediated by a transcytosis mechanism (F ig. 3-4 
and Fig. 3-6 respectively). Fluorescence images were consistent with the presence of 
FITC-albumin vesicles (green) detected inside endothelial cells which appeared to align 
along the phalloidin-labeled F-actin cytoskeleton (red) (Fig. 3-4). We next examined the 
co-localization of FITC-albumin with an anti-Tbdn monoclonal antibody (Martin et al., 
2007). Figure 3-5 depicts individual staining of FTTC-albumin (green), Tbdn (red) 
concentrated in the perinuclear region, nuclei shown by DAPI (blue) and a merged 
picture taken after 60 minute of incubation with 10 flM of FITC-albumin. There was no 
co-localization seen between FITC-albumin and Tbdn staining. 
3.3 FITC-albumin uptake in parental and antisense clones. Measurements of 
intracellular uptake of FITC-albumin by RF/6A endothelial cell monolayers by 
spectrofluorometry indicated a linear increase from 0 to 120 min (F ig. 3-6). There was no 
statistically significant difference between RF/6A parental endothelial cells, ASTB#l and 
CTR#l. This measurement was specific to albumin as the fluorescence signal was 
competed by excess unlabeled albumin (data not shown). 
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3.4 In vivo measurement of FITC-albumin. Barrier function is an important 
functional property of retinal endothelial cells that usually limits plasma albumin to 
intravascular areas (blood vessel lumens) in normal disease-free neural retinal tissues 
(Pino and Thouron, 1983; Liao and Gonzalez-Fernandez, 2004) as shown by albumin 
immunostaining of sections of control mouse retina (Fig. 3-7 A). The effect of Tbdn loss 
on the permeability of retinal endothelial cells to albumin was next examined in mice in 
vivo. A previously described conditional endothelial specific transgenic Tbdn-
knockdown mouse model (Wall et al., 2004) was used for these experiments. The 
conditional endothelial knockdown ofTbdn in adult mice is associated with fibrovascular 
growth and thickening of the retinal tissues (Wall et al., 2004) (Fig. 3-7 B,F). Compared 
to control age matched mice (Fig. 3-7 A), the abnormal blood vessels in retinal 
neovascular lesions of Tbdn knockdown mice leaked albumin as shown by staining of 
extravasated albumin (Fig. 3-78). The leakage was most significant from inner retinal 
blood vessels which are situated in areas in which we have previously shown increases in 
tissue thickness and abnormal fibrovascular growth (Wallet al., 2004). 
3.5 Expression of Z0-1 protein in RF/6A cells. One of the important molecules 
for maintaining the tight barrier in inter-endothelial junctions and regulating the 
paracellular permeability is Z0-1. We examined the protein expression of Z0 -1 in our 
parental, Tbdn knockdown clones and control clones (Fig. 3-8 A, B). There was no 
correlation seen between the permeability data (Fig. 3-2) and the level of Z0-1 in the 
parental or antisense clones. 
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Figure 3-1. Protein expression level ofTubedown/Ard-1. A, RF/6A parental 
endothelial cells (Par), Tbdn knockdown clones AS-TBDN (ASTB#l and #2) and control 
clones (CTR#l and #2) analyzed by Western blot for Tbdn and Ardl expression (Top and 
middle panels, respectively). Blots were reprobed and analyzed for Tubulin as loading 
control (Bottom panel). A representative experiment is shown in A, while the average of 
Tbdn and Ardl levels ± s.e.m. are shown in B. 
28 
- 160 ';/!. 0 
-.... 140 
·-fn 
c:: 120 cu 
.= 100 
c:: 
·- 80 E 
::::J 60 
.c 
-<C 40 I 
0 20 t-
-LL 0 
~ ~" ~" ~"' ~"' <l ~~ ~<f) ~<lj ~~ v ~ ~~ v 
_ _j 
Fig. 3-2. Tbdn/ Ardl knockdown in endothelial cells is associated with increased 
cellular permeability. FITC-albumin transit across monolayers ofRF/6A knocked-down 
for Tbdn expression (ASTB#l and #2) or controls (Par, CTR#l and #2) expressed as 
percentage of control Par at 30 min. Significantly higher percentages of FITC-albumin 
transit are observed in two AS-TBDN clones (ASTB#l and #2) as compared to parental 
cells (Par) and two negative control clones (CTR#l and #2). Data shown in are expressed 
as mean +/- s.e.m. of four duplicate experiments in each group. 
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Figure 3-3. FITC-albumin permeability in RF/6A endothelial cells increases with 
time. Time-course of FITC-albumin transit across cellular monolayers of Tbdn 
knockdown RF/6A cells (ASTB#l : filled square) as compared to parental cells (filled 
diamond) and control clone CTR#l cells (opened triangle) expressed as percentage of 
arbitrary units. Data shown are expressed as mean ± s.e.m. of four duplicate experiments 
in each group. Differences were considered significant at P<0.05. 
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Figure 3-4. FITC-albumin localization in the retinal endothelial cells. A-D, 
Fluorescence microscopy of FITC-albumin (A and D, green fluorescence) in RF/6A 
endothelial cells after 60 min. of incubation in the presence of FITC-albumin on cover 
slip and washes of excess of FITC-albumin, and staining for F-actin with phalloidin (B 
and D, ,red fluorescence). Cellular nuclei are highlighted by DAPI staining (C and D, blue 
fluorescence). The image in D represents the merge images of A, Band C. The scale bar 
shown in D represents 20 IJ.ID while the magnification is 400X for A-D. 
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Figure 3-5. Intracellular localization ofFITC-albumin and Tubedown in RF/6A 
cells. RF /6A parental endothelial cells cultured on glass coverslips were incubated with 
FITC-albumin tracer (A, green) and OE5 anti-Tbdn antibody (C, red) for overnight at 
room temperature. Panel B shows staining of the nuclei by DAPI (blue). The image in D 
illustrate the merge images of A,B and C. The scale bar shown in D represents 20 ~m 
while the magnification is 400X for A-D. 
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Figure 3-6. Quantitative analysis ofFITC-albumin uptake by RF/6A cells as a 
function of time. Intracellular FITC-albumin uptake increased with time. There was no 
statistically significant difference between the RF/6A par cells and the ASTB #1 and 
CTR# 1 clones, p::;:-0.05, n=3 experiments. Data are expressed as the mean of pmol per J.tg 
of protein ± s.e.m. 
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Figure 3-7. Extravasation of serum albumin through the retinal-blood barrier in 
endothelial-specific-Tbdn-knockdown mice. Staining of retinal tissue for albumin was 
performed using a peroxidase-conjugated goat anti-albumin antibody, which yields a 
brown reaction product. Compared with control (non-induced single transgenic is shown) 
age-matched mice (A), endothelial specific- Tbdn-knockdown eyes (B) showed 
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(B) showed significant leakage or extravasation of albumin (brown staining) from retinal 
blood vessels. Brown albumin staining is confmed mainly to blood vessel lumens in 
control retinas (A), whereas brown albumin staining is observed in extravascular 
locations both in and around blood vessels and in neural retinal tissues in Tbdn 
knockdown eyes (B). (C,D) Control (C) and Tbdn-knockdown (D) sections stained with 
negative-control horse-radish-peroxidase-conjugated goat anti rabbit lgG at the same 
concentration as the anti-albumin reagent showed no staining. All images show the inner 
and some of the outer layers of the neural retina (most are visible in E) and are oriented 
with the vitreous cavity (v) of the eye at the bottom of the panel. The ganglion cell layer 
and inner limiting membrane, which are immediately adjacent to the vitreous (v), are 
arrowed near the bottom of panels A-D. (E,F) Hematoxylin and Eosin staining of 
adjacent sections, revealing thickening of the retina and abundant abnormal blood vessels 
in Tbdn-knockdown retina (F) compared with control retinal tissues (E). Arrowheads in 
A,B,E and F point to blood vessels; brackets indicate the inner retinal layers (inner 
limiting membrane and ganglion cell layer). Representative images are shown. 
Magnification is 400X. A-D are not counterstained in order to emphasize brown albumin 
staining in A and B and lack of staining in C and D. 
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Figure 3-8. Protein expression level of Z0-1 in retinal endothelial cells. A, RF/6A 
parental endothelial cells (Par), Tbdn knockdown clones AS-TBDN (ASTB#1 and #2) 
and control clones (CTR#1 and #2) analyzed by Western blot for Z0-1 expression (Top 
panel). Blots were reprobed and analyzed for ERK-1 as loading control (Bottom panel). 
A representative experiment is shown in A, while the average of Z0-1 levels +/- s.e.m. 
are shown in B, n=3 separate experiments. 
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CHAPTER4 
Discussion 
The Tbdn protein sequence contains several tetratricopeptide (TPR) repeats which are 
known to mediate protein-protein interactions (Gendron et al., 2000; Willis et al., 2002; 
Main et al., 2005). This information suggests that Tbdn may associate specifica lly with 
other proteins. Tbdn associates with the acetyl transferase ARD I (Sugiura et al. , 2003; 
Arnesen et al., 2005) to form the NATA complex and with the putative acetyl transferase 
NAT5 (Arnesen et al. , 2006c; Hou et al., 2007) forming a complex of still unknown 
function. Paradis et al. (2008) reported that Tbdn binds to the actin binding protein 
cortactin. Cortactin has been implicated in regulating the dynamics of the actin 
cytoskeleton such as cell migration, endocytosis and intracellular movement of vesicles 
and plays a role in the regulation of the endothelial barrier and endothelial cell 
permeability (Weed and Parsons, 2001; Daly, 2004; Mehta and Malik, 2006). 
Studies describing the role of cortactin and the actin cytoskeleton in post-Golgi 
mediated vesicle traffic and processing have emerged (Cao et al., 2005; Kessels and 
Qualmann, 2005; Egea et al., 2006). However, only a single study linking vesicle 
transport with Tbdn protein function has been reported by Asaumi and co-workers (2005) 
who presented data that the endocytosis of f3-amyloid precursor transmembrane protein 
from cell surface was inhibited by transient overexpression of the active NAT A complex 
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consisting of Tbdn and ARD I in transformed embryo kidney cells (HEK293). In 
addition, secretion of amyloid-P 1-40 which likely depends on the endocytosis of the P-
amyloid precursor protein was also suppressed by overexpression of NATA and this 
suppression required the overexpression of both ARD1 and Tbdn (Asaumi et al., 2005). 
These results are consistent with our findings that Tbdn suppression increased the transit 
of FITC-Iabeled albumin through a cellular monolayer. Our present results show that the 
transit of FITC-albumin across confluent monolayers of clones of Tbdn knockdown 
RF/6A endothelial cells was higher than that of control cells. Interestingly, knockdown of 
Tbdn in diverse cellular systems including the RF/6A endothelial cells (Fig. 3-1) has been 
associated with a reduction in ARD I levels (Hou et al, 2007; Polevoda et al, 2007). This 
observation suggests that Tbdn and ARD I together regulate FITC-albumin transit across 
endothelial cell monolayers. 
To further understand the mechanism of FITC-albumin transit the intracellular 
localization of FITC-albumin taken up by RF/6A cells was examined by fluorescence 
microscopy. Using phalloidin, an F-actin marker, it was observed that the FITC-albumin 
formed punctate like structures which were partly co-localized with the F-actin (Fig. 3-4). 
This observation was consistent with previously reported transcytotic mechanism for the 
permeability of FITC-albumin in retinal endothelial cells (Vinores et al., 1993a; Vinores 
et al., 1998). We did not see any co-localization between Tbdn and FITC-albumin (Fig. 
3-5) in the RF/6A cells. This finding indicates that Tbdn most probably is not involved in 
the regulation of the cargo of molecule that is found inside the cells but may interact with 
the vesicle on the outside (Fig.4-l ). 
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The fluorescence microscopy data were further supported by the measured uptake 
of FITC-albumin in the RF/6A cells (Fig. 3-6). The uptake of FITC-albumin increased 
gradually up to 120 min, but no significant difference was observed between the 
intracellular uptake amounts of FITC-albumin in Tbdn knockdown RF/6A cells and the 
control cells. This result may be explained by either a differential rate of uptake at the 
entry (endocytosis) or the exit (exocytosis) of the cargo or may be caused by receptor 
saturation in the vesicle, which limits the uptake of material after a certain time point. 
The specificity of the assay was confirmed by competing FITC-Iabeled albumin with 
excess unlabeled albumin (data not shown). 
The regulation of permeability of endothelial cells is known to be functionally 
important for maintaining proper blood-retina barrier and retinal function (Mehta and 
Malik, 2006). This property of retinal endothelial cells limits serum proteins such as 
albumin to intravascular spaces (blood vessel lumens) (Pino and Thouron, 1983· Liao and 
Gonzalez-Fernandez, 2004). Conversely, extravasation or leakage of serum albumin and 
other materials out of retinal blood vessels has been described as a marker of retinal 
blood vessel damage in humans with retinopathy (Vinores et al., 1990; Vinores, et al. , 
1993b) and has been reported in several rodent models of retina-blood barrier breakdown 
(Vinores et al., 1999; Liu et al., 2004; Tomasek et al., 2006). The breakdown of retinal-
blood barrier function has been shown to involve changes in permeability of retinal 
endothelial cells (Tomasek et al., 2006) and is associated with edema and thickening of 
retinal tissues (Gardner et al., 2002; Sander et al. , 2007). Our previous studies have 
shown that the loss of retinal endothelial Tbdn expression is associated with retinal 
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fibrovascular growth and thickening and occurs in a range of retinopathies including 
diabetic retinopathy in humans, retinopathy of prematurity in infants, oxygen-induced 
retinopathy in mice and in proliferative vitreoretinopathy in TGFP-null mice (Gendron et 
al., 2001; Paradis et al., 2002; Wall et al., 2004; Gendron et al., 2006). These specific 
types of retinopathies are known, in some cases, to involve not only retinal angiogenesis 
but also breakdown of the blood-retinal barrier and changes in retinal endothelial cel l 
permeability and integrity which are associated with extravasation of albumin (Vinores et 
al., 1990; Yinores, et al., 1993b). In the present study examination of endothelial specific 
Tbdn-knockdown mice revealed significant leakage of albumin from retinal blood vessels 
compared to control age matched mice (Fig. 3-7). These results are consistent with our in 
vitro data showing that the knockdown of Tbdn in retinal endothelial cel ls leads to 
increased permeability to FITC-albumin. Moreover, we have previously demonstrated 
that the same Tbdn knockdown RF/6A retinal endothelial cell clones showing increased 
permeability here also display significant increases in capillary formation in vitro 
(Paradis et al., 2002). Overall, our results raise the possibility that increased transfer of 
serum proteins such as albumin across endothelial cells in Tbdn suppressed blood vessels 
is a contributing factor to the retinal pathology present in the Tbdn knockdown mouse 
model of neovascular retinopathy. 
In light of cortactin's known role in regulation of the dynamics of the actin 
cytoskeleton, it was speculated that Tbdn might participate in an acetyltransferase 
complex with cortactin in a range of processes involving the regulation of the F-actin 
cytoskeleton in endothelial cells (Paradis et al., 2008). Our present results on the effects 
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of Tbdn on the transit of FITC-albumin across cellular monolayers support a model in 
which Tbdn is involved in at least one of these cytoskeletal-mediated structural processes 
in endothelial cells (Mehta and Malik, 2006). The transport of FITC-labeled albumin has 
been used to assess endothelial permeability in vitro (Vogel at al., 2001; Tuma and 
Hubbard, 2003; Irwin et al., 2005). Endothelial cell permeability and the transit of 
molecules across the endothelial cell barrier are dependent upon both paracellular 
pathways and receptor mediated transcellular processes. The paracellular pathway 
involves intercellular junctions while the transcellular pathway utilizes a vesicular system 
(Mehta and Malik, 2006). Previous studies have shown that albumin utilizes the 
transcellular pathway in retinal endothelial cells in vivo (Vinores et al, 1993a; Yinores et 
al., 1998). Our results suggest that FITC-Iabeled albumin transit across RF/6A 
endothelial cell monolayers occurs at least via intracellular vesicular transport (Fig. 3-4) 
as previously reported for albumin in retinal endothelial cells (Vinores et al., 1993a; 
Yinores et al., 1998). Our results together with previous studies (Asaumi et al., 2005) 
implicating Tbdn in the regulation of endocytosis which is necessary for transcellular 
transport of albumin, support the notion that Tbdn is involved in the regulation of 
transcellular permeability. Both the para- and transcellular pathways are dependent upon 
the actin cytoskeleton and cortactin likely plays a role in both processes (Tuma and 
Hubbard, 2003; Mehta and Malik, 2006). Cortactin has been demonstrated to interact 
with proteins which regulate intercellular junction dynamics while also interacting with 
proteins participating in the vesicular flux of molecules across endothelial layers (Weed 
and Parsons, 200 I; Daly, 2004; Mehta and Malik, 2006; Huang et al. , 2006). Moreover, 
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both pathways are important for vascular homeostasis (Tuma and Hubbard; Mehta and 
Malik, 2006). The effects of Tbdn on endothelial cell permeability are consistent with the 
role of Tbdn in the regulation of retinal vascular homeostasis (Wall et al., 2004). 
Nevertheless, the possibility of a role for Tbdn in paracellular permeability of endothelial 
cells will require further studies. We have looked to see if Tbdn regulates the level of 
Z0-1, a protein involved in the regulation of paracellular permeability, by measuring the 
expression level ofZ0-1 in vitro using RF/6A cell clones with suppressed levels ofTbdn. 
There does not appear to have been any correlation between the expression level of Z0-1 
and Tbdn levels although some clonal variability was observed (Fig. 3-8). This finding 
does not support a role for Tbdn in regulating the paracellular permeability. However, 
Tbdn knockdown clones could still influence the sub-cellular localization of Z0-1 , which 
is essential for the functional assembly of tight junctions (Stevenson et al. 1986) and 
therefore, indirectly affect the paracellular permeability. Based on our findings, we 
propose a model to explain the mechanism by which FITC-albumin permeability occur in 
RF/6A retinal endothelial cells and the possible role of Tbdn in mediating this 
permeability is shown in Fig.4-1 . 
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Figure 4-1 Proposed mechanism for transcytosis of FITC-albumin in the retinal 
endothelial cells and the role of Tbdn. Transcytosis pathway consists of both 
endocytosis and exocytosis. While it is not clear ifTbdn is involved in the endocytosis or 
the exocytosis pathway, the interaction ofTbdn with cortactin could mediate albumin 
transcytosis via either the TPR or syntaxin conserved binding domains found in the Tbdn 
protein sequence. 
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Conclusions 
Neovascular retinopathies including PDR, ROP and AMD are leading cause of 
blindness in the general population affecting the quality of patient's life significantly. 
It is therefore essential to get a thorough understanding of the molecular mechanisms 
underlying the cause of neovascular pathologies to prevent and treat these diseases. 
Previous investigations indicate that Tubedown is an important homeostatic factor for 
maintaining a healthy retinal vascular network (Gendron et al., 2000; Gendron et al. , 
2001; Paradis et al., 2002; Wallet al., 2005). Ocular diseases with neovascularization 
are often accompanied by a change in permeability (Erickson, 2007). Therefore, to 
provide a mechanistic view of the involvement of Tbdn in neovascular retinal 
diseases, we investigated here the role of Tbdn on the permeability of retinal 
endothelial cells. 
We have gathered evidence indicating that the level of Tubedown affects the 
permeability of RF/6A retinal endothelial cells in vitro and of retinal blood vessels in 
vivo to albumin. Immunofluorescence data indicate a transcellular pathway for 
shuttling FITC-albumin across the cell monolayer. Based on our results we have 
proposed a mechanism where Tbdn may play an important in regulating the 
permeability of retinal endothelial cells to albumin by interacting with the actin 
binding protein, cortactin via its conserved domains. This work implicates a 
functional role for Tbdn in blood-vessel permeability dynamics that are crucial for 
vascular homeostasis. Loss of Tbdn could have clinically relevant significance and 
Tbdn may be used as a future drug target. 
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